MARKET

GLUE

GLUE

Monte Rosa Therapeutics, Inc.
NASDAQ
18.28
-0.40
-2.14%
Opening 10:27 05/15 EDT
OPEN
18.46
PREV CLOSE
18.68
HIGH
18.54
LOW
17.93
VOLUME
143.19K
TURNOVER
--
52 WEEK HIGH
25.77
52 WEEK LOW
3.510
MARKET CAP
1.54B
P/E (TTM)
-12.4940
1D
5D
1M
3M
1Y
5Y
1D
Monte Rosa Therapeutics Price Target Raised to $31.00/Share From $30.00 by JP Morgan
Dow Jones · 3d ago
Monte Rosa Therapeutics Is Maintained at Overweight by JP Morgan
Dow Jones · 3d ago
JP Morgan Maintains Overweight on Monte Rosa Therapeutics, Raises Price Target to $31
Benzinga · 3d ago
Monte Rosa Therapeutics price target raised to $31 from $30 at JPMorgan
TipRanks · 4d ago
Weekly Report: what happened at GLUE last week (0504-0508)?
Weekly Report · 4d ago
A Look At Monte Rosa Therapeutics (GLUE) Valuation After Strong Recent Share Price Momentum
Simply Wall St · 5d ago
Analysts Conflicted on These Healthcare Names: Monte Rosa Therapeutics (GLUE) and Beam Therapeutics (BEAM)
TipRanks · 6d ago
Analysts Offer Insights on Healthcare Companies: Foghorn Therapeutics (FHTX) and Monte Rosa Therapeutics (GLUE)
TipRanks · 05/07 19:20
More
About GLUE
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.

Webull offers Monte Rosa Therapeutics Inc stock information, including NASDAQ: GLUE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GLUE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GLUE stock methods without spending real money on the virtual paper trading platform.